Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 19/20 | 0.56 |
| ▸ | MMP3 | P08254 | 12/20 | 0.56 |
| ▸ | MMP7 | P09237 | 11/20 | 0.56 |
| ▸ | MMP2 | P08253 | 10/20 | 0.56 |
| ▸ | MMP13 | P45452 | 9/20 | 0.56 |
| ▸ | MMP9 | P14780 | 7/20 | 0.56 |
| ▸ | ADAM17 | P78536 | 5/20 | 0.56 |
| ▸ | MMP8 | P22894 | 5/20 | 0.56 |
| ▸ | MMP14 | P50281 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7765223 | 1.00 | MMP1 (0.56) | MMP1MMP3MMP7MMP2MMP13 | |
| SCHEMBL6339420 | 0.89 | MMP1 (0.68) | MMP1MMP3MMP7MMP2MMP13 | |
| SCHEMBL6112368 | 0.80 | MMP1 (0.80) | MMP1MMP3MMP7MMP2MMP13 | |
| SCHEMBL6108342 | 0.80 | MMP1 (0.80) | MMP1MMP3MMP7MMP2MMP13 | |
| SCHEMBL6107983 | 0.79 | MMP1 (0.59) | MMP1MMP3MMP7MMP2MMP13 | |
| SCHEMBL6863639 | 0.78 | MMP1 (0.56) | MMP1MMP3MMP7MMP2MMP13 | |
| SCHEMBL6336327 | 0.78 | MMP1 (0.56) | MMP1MMP3MMP7MMP2MMP13 | |
| SCHEMBL7408195 | 0.75 | MMP1 (0.43) | MMP1MMP3MMP7MMP2MMP13 | |
| SCHEMBL7763291 | 0.75 | MMP1 (0.56) | MMP1MMP3MMP7MMP2MMP13 | |
| SCHEMBL6267902 | 0.74 | MMP1 (0.67) | MMP1MMP3MMP7MMP2MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1098662-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2001-05-16 | — | — | EP | claimed |
| WO-2000004892-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2000-02-03 | — | — | WO | claimed |